Pulmonx's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Pulmonx's ROA in the second quarter of 2026?
Pulmonx Corporation recorded a cumulative net loss of $-48 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -38.32%.

However, within the Healthcare sector 472 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3784, from total ROA ranking in the first quarter of 2026 at 4421.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	-22.05 %	-20.41 %	-11.13 %	-8.57 %	-5.24 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-48	-53	-54	-57	-57
Return On Assets (TTM)	-38.32 %	-39.8 %	-38.2 %	-39.03 %	-38.3 %
LUNG's Total Ranking	# 3784	# 4421	# 3876	# 3888	# 3940
Total Assets (TTM) in million	115	120	129	138	147
Seq. Total Assets Change	-4.36 %	-7.21 %	-6.5 %	-6.05 %	-2.35 %
Seq. Net Income Change	-	-	-	-	-

LUNG's 5 Years Annual ROA >> Back to LUNG Management Effectiveness >> Compare LUNG ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 134
Sector	# 473
Overall	# 3730

Return On Assets Statistics
High	Average	Low
200.56 %	-14.46 %	-39.8 %
(Dec 31 2020)		(Mar 31 2026)

News about Pulmonx Corporation Return on Assets ROA

Pulmonx Corporation Instills Financial Expertise with New CFO Appointment, Aiming for Future Recovery and Innovation

Pulmonx Announces Appointment of Mehul Joshi as Chief Financial Officer: Assessing the Company s Financial Situation and Future Prospects
Pulmonx Corporation, a leader in minimally invasive treatments for lung disease, has recently appointed Mehul Joshi as its new Chief Financial Officer. The appointment comes after Pulmonx recorded a cumulative net loss of $-61 million during the twelve months ending in the fourth quarter of 2023, resulting in a negative return on assets (ROA) of -32.67%. These figures indicate significant financial challenges for the company.
The decision to bring Joshi on board may be viewed as a strategic move by Pulmonx to address its financial woes. With extensive experience in the field of finance, Joshi s expertise could prove invaluable in steering the company toward a more stable financial future. His appointment demonstrates a commitment by Pulmonx to effectively manage its financial operations and regain profitability.

Financial Statements
Pulmonx's Assets	$ 115 million	LUNG's Balance sheet
Pulmonx's Income	$ -10 million	Quarterly LUNG's Income Statement
LUNG's Income by Division		See LUNG's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-11.13 %	-16.78 %	-8.5 %	-16.7 %	-10.82 %
Total Assets in million	129	145	175	191	229
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-54	-56	-61	-59	-49
Annual Return On Assets	-41.77 %	-38.76 %	-34.8 %	-30.84 %	-21.22 %

LUNG's 5 Years Annual ROA >> Back to LUNG Management Effectiveness >> Compare LUNG ROA to its Competitors

More Return On Assets Ratios
LUNG's' Return on Assets at Yahoo Finance
Medical Equipment & Supplies Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
LUNG's Roa Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for LUNG's Competitors
Subscribers only: Roa for Pulmonx's Suppliers
Subscribers only: Return On Assets for LUNG's Customers

You may also want to know
LUNG's Roi	LUNG's Inventory Turnover Ratio	LUNG's Growth Rates	LUNG's Dividend Comparisons
	LUNG's Profitability Ratios	LUNG's Asset Turnover Ratio	LUNG's Dividend Growth
LUNG's Roe	LUNG's Valuation Ratios	LUNG's Financial Strength Ratios	LUNG's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-26T07:38:37+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.